MX2022007676A - Anticuerpos caninizados biespecificos para tratar dermatitis atopica. - Google Patents

Anticuerpos caninizados biespecificos para tratar dermatitis atopica.

Info

Publication number
MX2022007676A
MX2022007676A MX2022007676A MX2022007676A MX2022007676A MX 2022007676 A MX2022007676 A MX 2022007676A MX 2022007676 A MX2022007676 A MX 2022007676A MX 2022007676 A MX2022007676 A MX 2022007676A MX 2022007676 A MX2022007676 A MX 2022007676A
Authority
MX
Mexico
Prior art keywords
antibody
bispecific
atopic dermatitis
caninized anti
caninized
Prior art date
Application number
MX2022007676A
Other languages
English (en)
Inventor
Mohamad Morsey
Yuanzheng Zhang
Anasuya Saha
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2022007676A publication Critical patent/MX2022007676A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención proporciona composiciones para tratar la dermatitis atópica canina, que comprende un anticuerpo caninizado anti-proliferativo, un anticuerpo caninizado anti-prurítico, y un anticuerpo caninizado anti-inflamatorio. La presente invención se refiere además a composiciones que comprenden un anticuerpo biespecífico que comprende un anticuerpo caninizado anti-prurítico y un anticuerpo caninizado anti-proliferativo o alternativamente un anticuerpo biespecífico que comprende un anticuerpo caninizado anti-prurítico y un anticuerpo caninizado anti-inflamatorio.
MX2022007676A 2019-12-20 2020-12-18 Anticuerpos caninizados biespecificos para tratar dermatitis atopica. MX2022007676A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962951778P 2019-12-20 2019-12-20
US201962951793P 2019-12-20 2019-12-20
US202063015209P 2020-04-24 2020-04-24
US202063015220P 2020-04-24 2020-04-24
US202063092296P 2020-10-15 2020-10-15
US202063092294P 2020-10-15 2020-10-15
PCT/EP2020/086922 WO2021123092A1 (en) 2019-12-20 2020-12-18 Bispecific caninized antibodies for treating atopic dermatitis

Publications (1)

Publication Number Publication Date
MX2022007676A true MX2022007676A (es) 2022-07-19

Family

ID=74183110

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022007636A MX2022007636A (es) 2019-12-20 2020-12-18 Anticuerpos biespecificos caninizados y pares de union biespecificos para el tratamiento contra dermatitis atopica.
MX2022007676A MX2022007676A (es) 2019-12-20 2020-12-18 Anticuerpos caninizados biespecificos para tratar dermatitis atopica.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2022007636A MX2022007636A (es) 2019-12-20 2020-12-18 Anticuerpos biespecificos caninizados y pares de union biespecificos para el tratamiento contra dermatitis atopica.

Country Status (9)

Country Link
US (2) US20230250177A1 (es)
EP (2) EP4077380A1 (es)
JP (2) JP2023506922A (es)
CN (2) CN114829397A (es)
AU (2) AU2020407269A1 (es)
BR (2) BR112022011669A2 (es)
CA (2) CA3161496A1 (es)
MX (2) MX2022007636A (es)
WO (2) WO2021123094A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
GB202005879D0 (en) * 2020-04-22 2020-06-03 Petmedix Ltd Heterodimeric proteins
WO2023021169A1 (en) * 2021-08-20 2023-02-23 Intervet International B.V. Antibodies and igg fusion proteins with an extended half-life
WO2023111128A1 (en) * 2021-12-16 2023-06-22 Intervet International B.V. Caninized antibodies to canine interleukin-31 receptor alpha ii
CA3223956A1 (en) 2021-12-20 2023-06-29 Vetoquinol Sa Anti-canine interleukine-31-receptor a (il-31ra) antibodies and the uses thereof
CN115364223A (zh) * 2022-08-17 2022-11-22 郑州可尔利尔生物科技有限公司 作用于stat 6靶点的物质成分在制备治疗慢性瘙痒症的药物中的应用
CN115505575B (zh) * 2022-11-16 2023-03-24 中国科学院天津工业生物技术研究所 两株分泌犬il-31单克隆抗体的杂交瘤细胞株及其应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7696222B2 (en) 2005-08-12 2010-04-13 Merck Frosst Canada Ltd Indole derivatives as CRTH2 receptor antagonists
JP4884570B2 (ja) 2008-08-20 2012-02-29 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
AU2009295230A1 (en) 2008-09-22 2010-03-25 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
JP2012502926A (ja) 2008-09-22 2012-02-02 メルク カナダ インコーポレイテッド Ｃｒｔｈ２受容体アンタゴニストとしてのインドール誘導体
WO2010031184A1 (en) 2008-09-22 2010-03-25 Merck Frosst Canada Ltd. Azaindole derivatives as crth2 receptor antagonists
EP2401269B1 (en) 2009-02-24 2014-01-29 Merck Sharp & Dohme Corp. Indole derivatives as crth2 receptor antagonists
BR112012014703B1 (pt) 2009-12-17 2021-08-03 Merck Sharp & Dohme Corp. Composto aminopirimidina inibidor de syk, e, composição farmacêutica
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
DK3083694T3 (da) 2013-12-20 2024-01-29 Intervet Int Bv Caniniserede, murine anti-canin-pd-1-antistoffer
EP3954710A3 (en) 2015-04-02 2022-07-20 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
WO2017102920A1 (en) * 2015-12-18 2017-06-22 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
WO2017186928A1 (en) * 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
AU2017376398B2 (en) 2016-12-14 2021-07-15 Intervet International B.V. Aminopyrazoles as selective janus kinase inhibitors
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
WO2018156367A1 (en) * 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use

Also Published As

Publication number Publication date
EP4077379A1 (en) 2022-10-26
WO2021123092A1 (en) 2021-06-24
JP2023506925A (ja) 2023-02-20
CN114829397A (zh) 2022-07-29
US20230295289A1 (en) 2023-09-21
BR112022011669A2 (pt) 2022-09-06
CA3161496A1 (en) 2021-06-24
CA3161728A1 (en) 2021-06-24
JP2023506922A (ja) 2023-02-20
US20230250177A1 (en) 2023-08-10
AU2020406738A1 (en) 2022-06-23
BR112022011629A2 (pt) 2022-09-13
WO2021123094A1 (en) 2021-06-24
AU2020407269A1 (en) 2022-06-16
MX2022007636A (es) 2022-07-19
CN114829396A (zh) 2022-07-29
EP4077380A1 (en) 2022-10-26

Similar Documents

Publication Publication Date Title
MX2022007676A (es) Anticuerpos caninizados biespecificos para tratar dermatitis atopica.
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
PH12018500635A1 (en) Bispecific antibodies specific for pd1 and tim3
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
SG10201901057UA (en) Anti-pd-l1 antibodies
SG10201900571YA (en) Anti-pd-1 antibodies
MX2018000347A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
NZ736728A (en) Cd123 antibodies and conjugates thereof
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
MX2021016098A (es) Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas.
MY189618A (en) Antibody specifically binding to pd-1 and functional fragment thereof
PH12020550964A1 (en) Heavy chain antibodies binding to cd22
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
MX2019011585A (es) Anticuerpos miltiespecificos estables.
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
BR112021011529A2 (pt) Método para produção de um anticorpo heterodimérico, e, anticorpo biespecífico isolado
MX2021000797A (es) Anticuerpos agonistas de cd226.
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
WO2018227063A8 (en) Anti-robo2 antibodies, compositions, methods and uses thereof
MX2020010092A (es) Variantes de anticuerpo c-terminales.
EP4218817A3 (en) Methods for treating metabolic diseases by inhibiting myostatin activation
PH12021550991A1 (en) Monoclonal antibody that specifically binds to cd20